TriangleNCT00513435 · OUTCOME
Overall Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- From the start of treatment for up to 12 weeks
What was measured
Response was determined as inicated in the protocol.
Groups in this outcome
Treatment (Enzyme Inhibitor Therapy)
Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 9 |
Reported measurements
Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 1 | Not reported | Not reported | Not reported | Not reported |
Progression of Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 8 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- title
- Stable Disease
- categories
- measurements
- group Id
- OG000
- value
- 8
- title
- Progression of Disease
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- description
- Response was determined as inicated in the protocol.
- groups
- description
- Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- From the start of treatment for up to 12 weeks
- title
- Overall Response Rate
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice